In addition to dopaminergic and motor deficits, patients with Parkinson's disease (PD) suffer from non-motor symptoms, including early cognitive and social impairment, that do not respond well to dopaminergic therapy. Cholinergic deficits may contribute to these problems, but cholinesterase inhibitors have limited efficacy. Mice over-expressing α-synuclein, a protein critically associated with PD, show deficits in cognitive and social interaction tests, as well as a decrease in cortical acetylcholine. We have evaluated the effects of chronic administration of nicotine in mice over-expressing wild type human α-synuclein under the Thy1-promoter (Thy1-aSyn mice). Nicotine was administered subcutaneously by osmotic minipump for 6 months from 2 to 8 months of age at 0.4 mg/kg/h and 2.0 mg/kg/h. The higher dose was toxic in the Thy1-aSyn mice, but the low dose was well tolerated and both doses ameliorated cognitive impairment in Y-maze performance after 5 months of treatment. In a separate cohort of Thy1-aSyn mice, nicotine was administered at the lower dose for one month beginning at 5 months of age. This treatment partially eliminated the cognitive deficit in novel object recognition and social impairment. In contrast, chronic nicotine did not improve motor deficits after 2, 4 or 6 months of treatment, nor modified α-synuclein aggregation, tyrosine hydroxylase immunostaining, synaptic and dendritic markers, or microglial activation in Thy1-aSyn mice. These results suggest that cognitive and social impairment in synucleinopathies like PD may result from deficits in cholinergic neurotransmission and may benefit from chronic administration of nicotinic agonists.
Introduction
In patients with Parkinson's disease (PD), neurodegeneration primarily affects dopaminergic neurons of the substantia nigra (SN) of the midbrain, leading to dopamine loss in the striatum and dysregulation of neuronal circuits in the basal ganglia. This dopaminergic deficit is the primary cause of the characteristic motor symptoms of the disease, bradykinesia, resting tremor, and rigidity. However, the symptoms of PD extend beyond motor dysfunction and also involve non-motor aspects that include cognitive deficits, social impairment, sleep disturbances, and sensory and autonomic dysfunction (Anderson et al., 2013; Bassetti, 2011; Chaudhuri et al., 2011; Wolters, 2009) . The mechanisms of these non-motor symptoms of PD are only partially understood. Dopamine depletion may play a role in non-motor deficits; but their early appearance, often before motor deficits, and their poor response to dopaminergic treatments suggest additional mechanisms (Abbott et al., 2007; Postuma et al., 2012; Ross et al., 2006) .
α-synuclein has emerged as a potential pathogenic factor in PD based on genetic evidence that mutation or gene duplication in the SNCA gene cause familial forms of PD, and polymorphisms are strongly associated with sporadic PD (Edwards et al., 2010; Kruger et al., 1998; Polymeropoulos et al., 1997; Singleton et al., 2003) . Furthermore, α-synuclein is a component of Lewy bodies, a hallmark of PD, and forms aggregates that are broadly distributed in the central and peripheral nervous system (Bloch et al., 2006; Braak et al., 2006; Spillantini and Goedert, 2000; Spillantini et al., 1997) . The hypothesis that α-synuclein pathology may contribute to non-motor deficits in PD is supported by experimental evidence that mouse models of α-synuclein over-expression display deficits in behaviors also affected in early PD (Chesselet et al., 2012; Hatami and Chesselet, 2015; Magen and Chesselet, 2011) . This has been extensively characterized in mice over-expressing α-synuclein under the Thy1 promoter developed by Eliezer Masliah (Thy1-
